Recent news highlights Zomedica's Q1 2025 financial results, reporting a net loss and revenue performance.

• Zomedica Corp. reported a net loss for Q1 2025 and revenue that lagged prior expectations, reflecting ongoing operational challenges [N1].

Zomedica's strategic acquisitions have expanded its product offerings and manufacturing capabilities, positioning it to serve a broad veterinary market. The TRUFORMA platform's unique technology and exclusive assays provide differentiation in point-of-care diagnostics. The company has demonstrated revenue growth from $0 in 2020 to $32 million in 2025, indicating market adoption. Its diversified revenue streams across diagnostics, therapeutic devices, and development services may support operational resilience. The company's liquidity position with a strong current ratio and cash reserves supports ongoing operations and potential growth initiatives.

Zomedica has incurred significant net losses and negative cash flows since inception, with an accumulated deficit exceeding $295 million as of September 2025. The company faces risks related to market adoption of its products, competitive pressures, and the need for continued capital to fund operations. Delisting from NYSE American and trading on OTCQB may impact investor perception and liquidity. The company's reliance on a limited number of key products and the veterinary market's size and growth dynamics present challenges. Operational execution risks include managing integration of acquisitions and maintaining manufacturing and supply chain stability.

Zomedica's moat is based on its specialized focus on companion animal diagnostics and therapeutics, leveraging patented Bulk Acoustic Wave technology in its TRUFORMA platform and a portfolio of unique assays not available elsewhere at point of care. The company benefits from a diversified product portfolio across diagnostics and therapeutic devices, supported by a significant patent portfolio and ISO 13485 certified manufacturing facilities. Its established distribution network, including direct sales and partnerships with major veterinary distributors, enhances market reach. The relatively faster and less costly development cycle for companion animal medical devices compared to human devices provides a competitive advantage in product innovation and commercialization speed.

• Market Adoption Risk: The company depends on veterinarians adopting its diagnostic and therapeutic products, which may be affected by competition, clinical acceptance, and economic conditions in veterinary practices.
• Financial Sustainability Risk: Zomedica has a history of net losses and negative cash flows, requiring ongoing capital to fund operations and growth, which may be challenging to secure on favorable terms.
• Regulatory and Manufacturing Risk: Although companion animal devices face fewer regulatory hurdles than human devices, manufacturing disruptions, supply chain issues, or quality control problems could impact product availability and reputation.
• Market Listing and Liquidity Risk: Delisting from NYSE American and trading on OTCQB may reduce stock liquidity and investor interest, potentially affecting the company's ability to raise capital.

• Zomedica Corp. is an animal health company focused on companion animals such as dogs, cats, and horses, targeting clinical veterinarians as customers [S1].
• The company develops and markets diagnostic and therapeutic medical devices aimed at improving patient care and the economic health of veterinary practices [S1].
• Zomedica's product portfolio includes diagnostic platforms such as TRUFORMA, VETGuardian, and TRUVIEW, and therapeutic devices including Assisi, PulseVet, and VETIGEL [S1].
• The TRUFORMA platform uses patented Bulk Acoustic Wave technology for point-of-care diagnostics with assays for various animal hormones and diseases [S1].
• The company has grown through acquisitions, including Structured Monitoring Products, Inc. and Qorvo Biotechnologies, LLC, expanding its manufacturing, R&D, and commercial capabilities [S1].
• Zomedica operates three reportable segments: Diagnostics, Therapeutic Devices, and Development Services (contract manufacturing and engineering services) [S2,S19].
• The company manufactures and assembles products primarily in Roswell, Georgia, and Plymouth, Minnesota, with some contract manufacturing in Germany for Japan sales [S1,S2].
• Zomedica's common shares were delisted from NYSE American in March 2025 and began trading on OTCQB under ticker ZOMDF [S1].
• For the fiscal year ended December 31, 2025, Zomedica reported a net loss of $81.858 million and basic and diluted EPS of -$0.08 [S1].
• The company reported revenue of approximately $21.56 million for the year ended December 31, 2022, with growth in subsequent years to $32.0 million in 2025 [S1].
• Liquidity ratios as of December 31, 2025, include a current ratio of 6.78 and a cash ratio of 0.95, with cash and equivalents of $9.017 million and current assets of $64.043 million against current liabilities of $9.449 million [S1].
• Zomedica had an accumulated deficit of $295.243 million as of September 30, 2025 [S2].
• The company incurred operating losses and negative cash flows from operations since inception, with net losses continuing in recent periods [S2].
• Revenue is generated from sales of diagnostic instruments, consumables, therapeutic devices, and development services, with geographic sales primarily in the U.S. and foreign countries [S2,S20].
• The company provides product warranties varying from 3 to 24 months depending on the product [S1].
• Zomedica emphasizes rapid development and commercialization of companion animal diagnostics and therapeutics, which generally require less regulatory approval than human medical devices [S1].
• The company has ISO 13485 certification for its manufacturing and distribution operations [S1].
• Recent quarterly revenue for the three months ended September 30, 2025, was $8.095 million with a net loss of $6.121 million [N1,S2].
• Zomedica's business model includes direct sales, distributor relationships, and online retail channels domestically and internationally [S1].
• The company has a significant patent portfolio and marketing programs to support product adoption [S1].